| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 173.117 | 252.919 | 309.691 | 314.676 | 436.909 | 699.904 | 1.268.531 | 1.896.204 | 2.563.447 | 3.158.582 |
| Total Income - EUR | 173.326 | 254.448 | 311.670 | 314.676 | 436.910 | 700.756 | 1.290.391 | 1.913.628 | 2.611.131 | 3.158.586 |
| Total Expenses - EUR | 165.268 | 240.567 | 291.987 | 302.888 | 407.912 | 644.825 | 1.188.656 | 1.871.962 | 2.548.410 | 3.022.538 |
| Gross Profit/Loss - EUR | 8.058 | 13.881 | 19.683 | 11.788 | 28.998 | 55.931 | 101.735 | 41.666 | 62.721 | 136.048 |
| Net Profit/Loss - EUR | 6.769 | 11.660 | 15.573 | 8.641 | 24.628 | 48.924 | 86.377 | 35.851 | 54.384 | 114.280 |
| Employees | 7 | 9 | 8 | 9 | 11 | 13 | 15 | 29 | 23 | 25 |
Check the financial reports for the company - Mado G.pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 950 | 0 | 0 | 3.632 | 35.834 | 36.491 | 355.390 | 726.891 | 645.419 | 618.405 |
| Current Assets | 60.083 | 82.195 | 83.308 | 105.775 | 129.171 | 208.014 | 361.984 | 607.582 | 630.862 | 715.326 |
| Inventories | 54.016 | 74.824 | 66.028 | 83.102 | 108.988 | 120.829 | 236.198 | 447.081 | 515.260 | 578.618 |
| Receivables | 5.050 | 815 | 16.609 | 21.247 | 14.469 | 83.727 | 116.422 | 155.105 | 201.767 | 281.705 |
| Cash | 1.017 | 6.557 | 671 | 1.427 | 5.714 | 3.458 | 9.364 | 5.397 | -86.165 | -144.998 |
| Shareholders Funds | -3.447 | 8.248 | 23.682 | 31.607 | 55.624 | 103.493 | 173.571 | 169.405 | 77.994 | 78.608 |
| Social Capital | 45 | 45 | 44 | 43 | 0 | 0 | 0 | 0 | 0 | 70.362 |
| Debts | 64.479 | 73.947 | 59.626 | 77.800 | 109.381 | 141.012 | 543.803 | 1.165.068 | 1.198.287 | 1.255.122 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Mado G.pharma Srl